Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metformin + topiramate is a combination of two small molecule drugs, metformin and topiramate, used off-label primarily for weight loss in specific populations such as women with obesity and polycystic ovary syndrome (PCOS). Metformin is an oral antihyperglycemic agent that improves insulin sensitivity and reduces hepatic glucose production. Topiramate is an anticonvulsant that also has appetite-suppressing effects, though its exact mechanism for weight loss is not fully understood. The combination has been shown to result in greater weight loss compared to metformin alone and may improve metabolic parameters such as androgen levels, lipid profiles, and markers of inflammation. However, the use of this combination requires careful monitoring due to the risk of lactic acidosis when these drugs are used together[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metformin + topiramate.